To study improvement in patients with Obsessive Compulsive Disorder with add-on Intravenous Ketamine vs placebo

To study Efficacy and safety of Add-on Intravenous Ketamine in Obsessive Compulsive Disorder : A Pilot Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062696

Enrollment

Registered

2024-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Ketamine: Test group- 0.5 mg per kg body weight Ketamine in 50ml normal saline intravenous over 40 minutes Control Intervention1: Normal Saline: Control group - Injection Normal Saline

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Obsessive Compulsive Disorder according to ICD-10 and having Y-BOCS score more than 16 Duration more than 6 months with one failed trial of either SSRI or Clomipramine Patients who give their consent

Exclusion criteria

Exclusion criteria: Patients who do not give their informed consent. Patients with present diagnosis of cardiovascular disorders, glaucoma, raised intracranial pressure and history of head trauma Pregnant and lactating females Patients with current diagnosis of schizophrenia Patients diagnosed with Mental Retardation Patients having hypersensitivity to ketamine Patients with diagnosis of severe depression

Design outcomes

Primary

Measure	Time frame
To assess the effect of intravenous Ketamine in reducing the intensity of Obsessive Compulsive Symptoms within two weeks of administrationTimepoint: To assess the effect of intravenous Ketamine in reducing the intensity of Obsessive Compulsive Symptoms First assessment at baseline, then on every third day after receiving the infusion (day 0,day 3,day 6,day 9,day 12,day 15) Then weekly assessment for 4 weeks	—

Measure

Time frame

To assess the effect of intravenous Ketamine in reducing the intensity of Obsessive Compulsive Symptoms within two weeks of administrationTimepoint: To assess the effect of intravenous Ketamine in reducing the intensity of Obsessive Compulsive Symptoms First assessment at baseline, then on every third day after receiving the infusion (day 0,day 3,day 6,day 9,day 12,day 15) Then weekly assessment for 4 weeks

—

Secondary

Measure	Time frame
To assess phenomenological characteristics which favour response to Ketamine To assess safety of administration and Adverse Drug Reaction following KetamineTimepoint: To Follow up patient using side effect checklist	—

Countries

India

Contacts

Public ContactAashi Srivastava

Kalinga Institute of Medical Sciences

linksudipta@gmail.com9439728347

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026